Literature DB >> 19566481

The role of natalizumab in hematopoietic stem cell mobilization.

Frank Neumann1, Fabian Zohren, Rainer Haas.   

Abstract

The humanized monoclonal very late antigen 4 (VLA-4) antibody natalizumab is FDA approved for the treatment of patients with multiple sclerosis and Crohn's disease. In this review we focus on its role in the context of hematopoietic stem cell transplantation and stem cell diseases. The use of natalizumab alone or in combination with either cytotoxic drugs or other antibodies might be a new modality for stem cell mobilization and a therapeutic option for patients with hematologic malignancies.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19566481     DOI： 10.1517/14712590903055011

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN： 1471-2598            Impact factor:   4.388


  9 in total

Review 1.  Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.

Authors:  A Bellizzi; C Nardis; E Anzivino; D M Rodìo; D Fioriti; M Mischitelli; F Chiarini; V Pietropaolo
Journal:  J Neurovirol       Date:  2012-02       Impact factor: 2.643

2.  Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.

Authors:  Marek Mraz; Clive S Zent; Amy K Church; Diane F Jelinek; Xiaosheng Wu; Sarka Pospisilova; Stephen M Ansell; Anne J Novak; Neil E Kay; Thomas E Witzig; Grzegorz S Nowakowski
Journal:  Br J Haematol       Date:  2011-07-12       Impact factor: 6.998

3.  The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab.

Authors:  Jan Kolcava; Monika Hulova; Lucie Rihova; Josef Bednarik; Pavel Stourac
Journal:  Neurol Sci       Date:  2020-11-17       Impact factor: 3.307

4.  Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study.

Authors:  Claire Bridel; Yan Beauverd; Kaveh Samii; Patrice H Lalive
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-06-18

Review 5.  Role of integrin alpha4 in drug resistance of leukemia.

Authors:  Stephanie Shishido; Halvard Bönig; Yong-Mi Kim
Journal:  Front Oncol       Date:  2014-05-23       Impact factor: 6.244

6.  Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.

Authors:  Valeria Pietropaolo; Anna Bellizzi; Elena Anzivino; Marco Iannetta; Maria Antonella Zingaropoli; Donatella Maria Rodio; Manuela Morreale; Simona Pontecorvo; Ada Francia; Vincenzo Vullo; Anna Teresa Palamara; Maria Rosa Ciardi
Journal:  J Neurovirol       Date:  2015-05-01       Impact factor: 2.643

7.  Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.

Authors:  Christian Wolf; Jagdev Sidhu; Christian Otoul; Dexter L Morris; Jennifer Cnops; Jorg Taubel; Barbara Bennett
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

Review 8.  New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy.

Authors:  Anna Bellizzi; Elena Anzivino; Donatella Maria Rodio; Anna Teresa Palamara; Lucia Nencioni; Valeria Pietropaolo
Journal:  Clin Dev Immunol       Date:  2013-04-17

9.  Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.

Authors:  Thomas F Benkert; Lena Dietz; Elena M Hartmann; Ellen Leich; Andreas Rosenwald; Edgar Serfling; Mathias Buttmann; Friederike Berberich-Siebelt
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.